SHR8028 eye drops + Vehicle eye drops.
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Eye Disease
Conditions
Dry Eye Disease
Trial Timeline
Mar 4, 2021 → Jul 22, 2022
NCT ID
NCT05841043About SHR8028 eye drops + Vehicle eye drops.
SHR8028 eye drops + Vehicle eye drops. is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05841043. Target conditions include Dry Eye Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05841043 | Phase 3 | Completed |
Competing Products
20 competing products in Dry Eye Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 49 |
| Abiprubart + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 52 |
| Rosuvastatin 40mg + Placebo | HeartFlow | Pre-clinical | 18 |
| Evolocumab | HeartFlow | Approved | 80 |
| High intensity lipid lowering | HeartFlow | Pre-clinical | 18 |
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Dulaglutide + Placebo | Eli Lilly | Phase 3 | 77 |
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| VTX958 + VTX958 + VTX958 Placebo | Ventyx Biosciences | Phase 2 | 47 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |